# Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

> **NCT04545710** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 18 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04545710
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-21
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04545710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04545710, "Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04545710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*